The filing confirms extreme financial distress and imminent Nasdaq delisting. The Psyga Bio acquisition closed concurrently, which may provide a short-term reprieve, but massive dilution and continued cash burn are likely. Monitor for Nasdaq compliance updates and any additional capital raises.
Price Chart
Executive Summary
XTL Biopharmaceuticals filed its FY2025 20-F revealing a net loss of $6.97M, cash of only $76k, and an accumulated deficit of $165.6M. The auditors issued a going-concern opinion, and the company faces Nasdaq delisting for multiple deficiencies. The Psyga Bio acquisition closed on June 30, 2026, providing a potential lifeline, but the standalone financials reflect severe distress.
Key Facts
- Net loss of $6,969,000 for FY2025, including a $6,210,000 loss from discontinued operations (Social Proxy deconsolidation).
- Cash and cash equivalents of $76,000 as of Dec 31, 2025, down from $371,000 a year earlier.
- Accumulated deficit of $165,632,000 as of Dec 31, 2025.
- Independent auditor included a going-concern explanatory paragraph.
- Management concluded a material weakness in internal control over financial reporting exists.
- Nasdaq delisting risk with multiple deficiencies (stockholders' equity, bid price, late filing); Panel granted exception contingent on Psyga Bio acquisition, which closed on June 30, 2026.
- No revenue from continuing operations in 2025; operating loss of $1,688,000.
Financial Impact
Net loss of $6.97 million for FY2025; cash burn rate suggests less than 3 months of runway without new capital.
Risk Factors
- Going concern risk: only $76k cash and no revenue.
- Nasdaq delisting could lead to OTC trading and loss of institutional access.
- Massive dilution from Psyga Bio acquisition (33.36% of post-issuance shares plus milestone shares).
- Psyga's early-stage psychedelic pipeline has no approved products and faces regulatory uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-073831 |
| Document: ea029609501ex1-1.htm | 0001213900-26-073831 |
| Document: ea029609501ex4-13.htm | 0001213900-26-073831 |
| Document: ea029609501ex12-1.htm | 0001213900-26-073831 |
| Document: ea029609501ex12-2.htm | 0001213900-26-073831 |
| Document: ea029609501ex13-1.htm | 0001213900-26-073831 |
| Document: ea029609501ex16-1.htm | 0001213900-26-073831 |
| Document: ea029609501ex8-1.htm | 0001213900-26-073831 |
| Document: 0001213900-26-073831-index-headers.html | 0001213900-26-073831 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 6-K | $1.91 | awaiting T+60 | — | $1.81 (−5.24%) |
Jun 30, 2026 17w ago | 20-F | $2.49 $2.41 | ▲ +3.21% | ▲ +6.08% | $1.81 (+27.31%) |
Jun 29, 2026 17w ago | 6-K | $2.73 $2.20 | ▼ −19.41% | ▼ −22.23% | $1.81 (−33.70%) |
May 22, 2026 22w ago | 6-K | $2.38 $2.98 | ▼ −25.21% | ▼ −22.49% | $1.81 (+23.95%) |
May 7, 2026 24w ago | 6-K | $2.67 $2.86 | ▲ +7.15% | ▲ +3.31% | $1.81 (−32.21%) |
Apr 29, 2026 25w ago | 6-K | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.81 (−49.16%) |
Apr 29, 2026 25w ago | Press Release | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.81 (−49.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers